EKF Diagnostics Holdings Plc is a vitro diagnostics company, which engages in the designs and manufactures diagnostic equipment for use within point-of-care settings. The company is headquartered in Penarth, South Glamorgan and currently employs 304 full-time employees. The company went IPO on 2002-06-05. The firm develops and produces in-vitro diagnostic (IVD) devices and tests designed for use at or near the patient’s location. The company provides a suite of products for diabetes management, including glucose monitoring systems and associated consumables. The company offers devices, supplies, and consumables for measuring hemoglobin levels, including tools for detecting hemoglobin variants. The company also develops and supplies diagnostic and therapeutic enzymes, proteins, reagents, and biomaterials. The company provides precision fermentation, custom bioprocessing, and contract manufacturing services for pharmaceuticals and other biological products. The company supplies beta-hydroxybutyrate (HB) products used in ketone detection to support the diagnosis of diabetic ketoacidosis and other clinical conditions.
Follow-Up Questions
EKF Diagnostics Holdings PLC のCEOは誰ですか？
Mr. Gavin Jones は EKF Diagnostics Holdings PLC の Chief Executive Officer で、2025 から在籍しています。
EKDHF の株価パフォーマンスは？
EKDHF の現在の価格は $0.4 で、最終取引日から 0% decreased 変動しました。
EKF Diagnostics Holdings PLC の主な事業テーマや業界は？
EKF Diagnostics Holdings PLC は Health Care 業界、セクターは Health Care に属しています。
